London
· Delayed Price · Currency is GBP · Price in USD Regeneron Pharmaceuticals Statistics
Total Valuation
LON:0R2M has a market cap or net worth of GBP 59.29 billion. The enterprise value is 47.45 billion.
| Market Cap | 59.29B |
| Enterprise Value | 47.45B |
Important Dates
The last earnings date was Monday, February 3, 2025.
| Earnings Date | Feb 3, 2025 |
| Ex-Dividend Date | Feb 20, 2025 |
Share Statistics
| Current Share Class | n/a |
| Shares Outstanding | n/a |
| Shares Change (YoY) | +1.23% |
| Shares Change (QoQ) | -2.07% |
| Owned by Insiders (%) | n/a |
| Owned by Institutions (%) | n/a |
| Float | 103.00M |
Valuation Ratios
The trailing PE ratio is 16.82.
| PE Ratio | 16.82 |
| Forward PE | n/a |
| PS Ratio | n/a |
| PB Ratio | n/a |
| P/TBV Ratio | 2.63 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
The stock's EV/EBITDA ratio is 12.86, with an EV/FCF ratio of 16.21.
| EV / Earnings | 13.46 |
| EV / Sales | 4.22 |
| EV / EBITDA | 12.86 |
| EV / EBIT | 14.47 |
| EV / FCF | 16.21 |
Financial Position
The company has a current ratio of 4.73, with a Debt / Equity ratio of 0.10.
| Current Ratio | 4.73 |
| Quick Ratio | 3.86 |
| Debt / Equity | 0.10 |
| Debt / EBITDA | 0.63 |
| Debt / FCF | 0.80 |
| Interest Coverage | 75.09 |
Financial Efficiency
Return on equity (ROE) is 15.95% and return on invested capital (ROIC) is 8.49%.
| Return on Equity (ROE) | 15.95% |
| Return on Assets (ROA) | 7.31% |
| Return on Invested Capital (ROIC) | 8.49% |
| Return on Capital Employed (ROCE) | 12.26% |
| Revenue Per Employee | 750,969 |
| Profits Per Employee | 233,328 |
| Employee Count | 15,106 |
| Asset Turnover | 0.40 |
| Inventory Turnover | 2.51 |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -25.85% in the last 52 weeks.
| Beta (5Y) | n/a |
| 52-Week Price Change | -25.85% |
| 50-Day Moving Average | 706.92 |
| 200-Day Moving Average | 933.93 |
| Relative Strength Index (RSI) | 52.53 |
| Average Volume (20 Days) | 1,998 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | 2.46 |
Income Statement
In the last 12 months, LON:0R2M had revenue of GBP 11.34 billion and earned 3.52 billion in profits. Earnings per share was 30.62.
| Revenue | 11.34B |
| Gross Profit | 5.67B |
| Operating Income | 3.31B |
| Pretax Income | 3.82B |
| Net Income | 3.52B |
| EBITDA | 3.70B |
| EBIT | 3.31B |
| Earnings Per Share (EPS) | 30.62 |
Balance Sheet
The company has 7.20 billion in cash and 2.35 billion in debt, giving a net cash position of 11.96 billion.
| Cash & Cash Equivalents | 7.20B |
| Total Debt | 2.35B |
| Net Cash | 11.96B |
| Net Cash Per Share | n/a |
| Equity (Book Value) | 23.45B |
| Book Value Per Share | 218.52 |
| Working Capital | 11.76B |
Cash Flow
In the last 12 months, operating cash flow was 3.53 billion and capital expenditures -603.79 million, giving a free cash flow of 2.93 billion.
| Operating Cash Flow | 3.53B |
| Capital Expenditures | -603.79M |
| Free Cash Flow | 2.93B |
| FCF Per Share | n/a |
Margins
Gross margin is 49.99%, with operating and profit margins of 29.19% and 31.07%.
| Gross Margin | 49.99% |
| Operating Margin | 29.19% |
| Pretax Margin | 33.66% |
| Profit Margin | 31.07% |
| EBITDA Margin | 32.59% |
| EBIT Margin | 29.19% |
| FCF Margin | 25.80% |
Dividends & Yields
LON:0R2M does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -1.23% |
| Shareholder Yield | -1.23% |
| Earnings Yield | 5.94% |
| FCF Yield | 4.94% |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
LON:0R2M has an Altman Z-Score of 9.82.
| Altman Z-Score | 9.82 |
| Piotroski F-Score | n/a |